Nano-Polymer Stents May Reach U.S. Market By 2007 At Half The Cost Of DES
This article was originally published in The Gray Sheet
Executive Summary
Polyphosphaze non-carbon-based nano-polymers potentially will offer the same anti-restenosis benefits as drug-eluting stents, but cost only slightly more than bare-metal versions, according to Götz Richter, MD/PhD, University of Heidelberg, Germany
You may also be interested in...
Can Better Polymers Challenge DES? Cost Barriers Spur German Alternative
Coronary stents coated with non-carbon-based polymers may prevent restenosis without bearing drugs, Götz Richter, MD/PhD, University of Heidelberg, Germany, asserted Nov. 18
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.